On March, 12 after the close. Investors wait Aptose Biosciences Inc. (NASDAQ:APTO) to announce its quarterly earnings, according to Zacks. The earnings per share diference is $0.04 or 33.33 % down from last years number. Previous year: $-0.12; Analysts forcast: $-0.16. 0.00 % EPS growth is what Wall Street’s sees after $-0.16 reported EPS last quarter. APTO is touching $1.64 during the last trading session, after decreased 2.96%.Currently Aptose Biosciences Inc. is downtrending after 37.96% change in last March 11, 2018. APTO has also 239,135 shares volume. APTO underperformed by 42.33% the S&P 500.

Aptose Biosciences Inc. (NASDAQ:APTO) Ratings Coverage

Total analysts of 4 have positions in Aptose Biosciences (NASDAQ:APTO) as follows: 4 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. The firm has $8.5 highest while $5 is the lowest PT. The average target $6.38 is 289.02% above the last ($1.64) price. Since November 16, 2018 according to StockzIntelligence Inc Aptose Biosciences has 4 analyst reports. The company rating was maintained by H.C. Wainwright on Monday, February 25. On Friday, March 1 the firm has “Buy” rating given by RBC Capital Markets.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada.The company has $67.16 million market cap. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.Currently it has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

For more Aptose Biosciences Inc. (NASDAQ:APTO) news published briefly go to: Globenewswire.com, Globenewswire.com, Globenewswire.com, Globenewswire.com or Streetinsider.com. The titles are as follows: “Aptose to Release Third Quarter Ended September 30, 2018 Financial Results on November 6, 2018 – GlobeNewswire” published on October 23, 2018, “Aptose to Present at Upcoming Investor Conferences in October 2018 – GlobeNewswire” on September 25, 2018, “Aptose Presents Preclinical Data on APTO-253 at 2018 AACR Annual Meeting – GlobeNewswire” with a publish date: April 17, 2018, “Aptose to Present at the 8th Annual SVB Leerink Global Healthcare Conference – GlobeNewswire” and the last “RBC Capital Starts Aptose Biosciences (APTO) at Outperform; Positive on CG-806 – StreetInsider.com” with publication date: March 01, 2019.